"L'Institut Paoli-Calmettes est chargé, par la loi, d'une mission de service public en matière de cancérologie. L’Institut Paoli-Calmettes, notamment à travers son nouveau projet d’établissement s’enracine dans le socle des valeurs communes aux centres de lutte contre le cancer dont l’IPC fait partie :- la quête d’excellence,- la solidarité, - l’humanité, - l’innovation dans la relation aux patients."

During the past decade, Institut Paoli-Calmettes - Hématologie Clinique conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 2 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut Paoli-Calmettes - Hématologie Clinique" #1 sponsor was "Groupe Francophone des Myelodysplasies" with 5 trials, followed by "French Innovative Leukemia Organisation" with 4 trials sponsored, "University Hospital, Lille" with 2 trials sponsored, "Celgene" with 1 trials sponsored and "Celgene Corporation" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Paoli-Calmettes - Hématologie Clinique" #1 collaborator was "Amgen" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Celgene Corporation" with 1 trials as a collaborator, "Janssen, LP" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Institut Paoli-Calmettes - Hématologie Clinique" are "Myelodysplastic Syndromes" (4 trials), "Multiple Myeloma" (3 trials), "Acute Myeloid Leukemia" (1 trials), "Bruton Tyrosine Kinase Inhibitor" (1 trials) and "CLL, Refractory" (1 trials). Many other conditions were trialed in "Institut Paoli-Calmettes - Hématologie Clinique" in a lesser frequency.

Most popular intervention types in "Institut Paoli-Calmettes - Hématologie Clinique" are "Drug" (12 trials). Other intervention types were less common.

The name of intervention was led by "ACA Continuation" (1 trials), "AG-120" (1 trials), "AG-221" (1 trials), "Azacitidine and LDE255" (1 trials) and "Azacitidine and oral vorinostat" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institut Paoli-Calmettes - Hématologie Clinique" are 13 trials for "All" genders.

Currently, there are NaN active trials in "Institut Paoli-Calmettes - Hématologie Clinique". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Institut Paoli-Calmettes - Hématologie Clinique, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institut Paoli-Calmettes - Hématologie Clinique, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".